C4 Therapeutics, a preclinical biotech developing small molecule protein degraders for cancer, filed on Thursday with the SEC to raise up to $100 million in an initial public offering. C4 has four preclinical programs for its small molecule protein...read more
Three drug developers and a medical imaging company went public this past week, joined by eight SPACs. Preclinical protein degradation biotech Kymera Therapeutics (KYMR) upsized and priced above the range to raise $174 million at a $938...read more
Kymera Therapeutics, a preclinical biotech developing protein degraders for oncology and immunology, raised $174 million by offering 8.7 million shares at $20, above the range of $16 to $18. The Watertown, MA-based company originally planned to offer 7.4...read more
Kymera Therapeutics, a preclinical biotech developing small molecule protein degrader therapies for inflammatory diseases, announced terms for its IPO on Monday.
The Watertown, MA-based company plans to raise $125 million by offering 7.4 million shares at a...read more
Explosive cancer treatments: Preclinical biotech C4 Therapeutics files for a $100 million IPO
C4 Therapeutics, a preclinical biotech developing small molecule protein degraders for cancer, filed on Thursday with the SEC to raise up to $100 million in an initial public offering. C4 has four preclinical programs for its small molecule protein...read more
US IPO Weekly Recap: Biotechs and SPACs ride the summer wave in a 4 IPO week
Three drug developers and a medical imaging company went public this past week, joined by eight SPACs. Preclinical protein degradation biotech Kymera Therapeutics (KYMR) upsized and priced above the range to raise $174 million at a $938...read more
Protein degrader biotech Kymera Therapeutics prices upsized IPO above the range at $20
Kymera Therapeutics, a preclinical biotech developing protein degraders for oncology and immunology, raised $174 million by offering 8.7 million shares at $20, above the range of $16 to $18. The Watertown, MA-based company originally planned to offer 7.4...read more
Preclinical inflammatory disease biotech Kymera Therapeutics sets terms for $125 million IPO
Kymera Therapeutics, a preclinical biotech developing small molecule protein degrader therapies for inflammatory diseases, announced terms for its IPO on Monday. The Watertown, MA-based company plans to raise $125 million by offering 7.4 million shares at a...read more